Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report

Immunotherapy through blocking programmed cell death 1, programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 is developing rapidly and has gained increasing attention as a treatment for malignant tumors. However, some patients experience varying degrees of immune-related side effects after...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Shixia, Liu, Kunjing, Liu, Ruijuan, Zhuang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468829/
https://www.ncbi.nlm.nih.gov/pubmed/36160895
http://dx.doi.org/10.3892/etm.2022.11554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468829/
https://www.ncbi.nlm.nih.gov/pubmed/36160895
http://dx.doi.org/10.3892/etm.2022.11554

Ejemplares similares